EA201300997A1 - ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ - Google Patents
ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯInfo
- Publication number
- EA201300997A1 EA201300997A1 EA201300997A EA201300997A EA201300997A1 EA 201300997 A1 EA201300997 A1 EA 201300997A1 EA 201300997 A EA201300997 A EA 201300997A EA 201300997 A EA201300997 A EA 201300997A EA 201300997 A1 EA201300997 A1 EA 201300997A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyrido
- therapeutic applications
- kinases
- derivatives
- pirazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Настоящее изобретение относится к новым пиридо[2,3-b]пиразиновым производным формулы (I) и к применению таких соединений, при котором играет роль ингибирование, регуляция и/или модуляция передачи сигналов с помощью АТФ-связывающих белков, подобных киназам, в частности к ингибиторам TGF-бета рецепторных киназ, и к применению таких соединений для лечения заболеваний, индуцированных киназами, в частности для лечения опухолей.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11001944 | 2011-03-09 | ||
PCT/EP2012/000630 WO2012119690A1 (en) | 2011-03-09 | 2012-02-13 | Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201300997A1 true EA201300997A1 (ru) | 2014-02-28 |
Family
ID=45607719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201300997A EA201300997A1 (ru) | 2011-03-09 | 2012-02-13 | ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ |
Country Status (16)
Country | Link |
---|---|
US (1) | US9051318B2 (ru) |
EP (1) | EP2683715B1 (ru) |
JP (1) | JP6104824B2 (ru) |
KR (1) | KR20140022829A (ru) |
CN (1) | CN103391938B (ru) |
AR (1) | AR085637A1 (ru) |
AU (1) | AU2012224979B2 (ru) |
BR (1) | BR112013022948A2 (ru) |
CA (1) | CA2829287C (ru) |
EA (1) | EA201300997A1 (ru) |
ES (1) | ES2542647T3 (ru) |
IL (1) | IL228265A (ru) |
MX (1) | MX2013010163A (ru) |
SG (1) | SG193301A1 (ru) |
WO (1) | WO2012119690A1 (ru) |
ZA (1) | ZA201307511B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2829287C (en) * | 2011-03-09 | 2019-12-17 | Merck Patent Gmbh | Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses |
AU2014373773C1 (en) | 2014-01-01 | 2019-06-27 | Medivation Technologies Llc | Compounds and methods of use |
JP6767875B2 (ja) * | 2014-04-08 | 2020-10-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
CN109053598B (zh) * | 2018-06-14 | 2021-04-13 | 温州大学 | 一种芳基取代喹唑啉化合物及其合成方法 |
US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1918299A (en) | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
WO2000061186A1 (en) | 1999-04-08 | 2000-10-19 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
EP1575506A4 (en) | 2002-07-25 | 2008-04-23 | Scios Inc | METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS |
EP1603908B1 (en) * | 2003-03-12 | 2008-06-11 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
WO2005023807A2 (en) | 2003-09-09 | 2005-03-17 | Neurogen Corporation | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists |
WO2005042498A2 (en) | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (aza) quinoline derivatives as capsaicin receptor agonists |
US20050245508A1 (en) | 2003-12-24 | 2005-11-03 | Scios, Inc. | Treatment of malignant gliomas with TGF-beta inhibitors |
TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
EP1836203A2 (en) | 2005-01-14 | 2007-09-26 | Neurogen Corporation | Heteroaryl substituted quinolin-4-ylamine analogues |
US7825137B2 (en) | 2005-12-05 | 2010-11-02 | Pfizer Inc. | Method of treating abnormal cell growth |
EP1990342A1 (en) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
JP4751856B2 (ja) | 2007-07-03 | 2011-08-17 | 本田技研工業株式会社 | 車体側部構造 |
GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
WO2010052448A2 (en) * | 2008-11-05 | 2010-05-14 | Ucb Pharma S.A. | Fused pyrazine derivatives as kinase inhibitors |
EP2391623A4 (en) * | 2009-02-02 | 2012-09-05 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
CA2829287C (en) * | 2011-03-09 | 2019-12-17 | Merck Patent Gmbh | Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses |
-
2012
- 2012-02-13 CA CA2829287A patent/CA2829287C/en not_active Expired - Fee Related
- 2012-02-13 ES ES12704233.1T patent/ES2542647T3/es active Active
- 2012-02-13 KR KR1020137026431A patent/KR20140022829A/ko not_active Application Discontinuation
- 2012-02-13 WO PCT/EP2012/000630 patent/WO2012119690A1/en active Application Filing
- 2012-02-13 BR BR112013022948A patent/BR112013022948A2/pt not_active Application Discontinuation
- 2012-02-13 JP JP2013556989A patent/JP6104824B2/ja not_active Expired - Fee Related
- 2012-02-13 AU AU2012224979A patent/AU2012224979B2/en not_active Ceased
- 2012-02-13 EA EA201300997A patent/EA201300997A1/ru unknown
- 2012-02-13 CN CN201280010974.7A patent/CN103391938B/zh not_active Expired - Fee Related
- 2012-02-13 EP EP12704233.1A patent/EP2683715B1/en not_active Not-in-force
- 2012-02-13 SG SG2013066550A patent/SG193301A1/en unknown
- 2012-02-13 MX MX2013010163A patent/MX2013010163A/es not_active Application Discontinuation
- 2012-02-13 US US14/002,991 patent/US9051318B2/en not_active Expired - Fee Related
- 2012-03-09 AR ARP120100764A patent/AR085637A1/es not_active Application Discontinuation
-
2013
- 2013-09-03 IL IL228265A patent/IL228265A/en active IP Right Grant
- 2013-10-08 ZA ZA2013/07511A patent/ZA201307511B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG193301A1 (en) | 2013-10-30 |
AU2012224979A1 (en) | 2013-10-24 |
CA2829287C (en) | 2019-12-17 |
JP6104824B2 (ja) | 2017-03-29 |
IL228265A (en) | 2016-12-29 |
AU2012224979B2 (en) | 2017-01-19 |
US9051318B2 (en) | 2015-06-09 |
MX2013010163A (es) | 2013-10-30 |
EP2683715A1 (en) | 2014-01-15 |
ZA201307511B (en) | 2016-08-31 |
CN103391938A (zh) | 2013-11-13 |
WO2012119690A1 (en) | 2012-09-13 |
KR20140022829A (ko) | 2014-02-25 |
EP2683715B1 (en) | 2015-04-15 |
CN103391938B (zh) | 2016-02-24 |
BR112013022948A2 (pt) | 2016-12-06 |
IL228265A0 (en) | 2013-11-25 |
AR085637A1 (es) | 2013-10-16 |
ES2542647T3 (es) | 2015-08-07 |
US20130345227A1 (en) | 2013-12-26 |
JP2014511390A (ja) | 2014-05-15 |
CA2829287A1 (en) | 2012-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201300080A1 (ru) | Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами | |
EA201300052A1 (ru) | [1,8]нафтиридиновые производные | |
PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
EA201291098A1 (ru) | Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
EA201070618A1 (ru) | 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201300997A1 (ru) | ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ | |
EA201291143A1 (ru) | Пиразолилхиназолиновые ингибиторы киназы | |
MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
BR112015026721A2 (pt) | derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer | |
EA201001242A1 (ru) | ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ | |
EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
EA201290878A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ | |
EA201491747A1 (ru) | Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов | |
PH12014500794A1 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
EA201290073A1 (ru) | Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ | |
MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
EA201491376A1 (ru) | Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы | |
EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv |